nach oben

Breast Cancer Research

Erschienen in:

01.02.2002 | Commentary

Intrauterine environment, mammary gland mass and breast cancer risk

verfasst von: Dimitrios Trichopoulos

Erschienen in: Breast Cancer Research | Ausgabe 1/2002

Einloggen, um Zugang zu erhalten

Abstract

Two intimately linked hypotheses on breast cancer etiology are described. The main postulate of the first hypothesis is that higher levels of pregnancy estrogens and other hormones favor the generation of a higher number of susceptible stem cells with compromised genomic stability. The second hypothesis postulates that the mammary gland mass, as a correlate of the number of cells susceptible to transformation, is an important determinant of breast cancer risk. A simple integrated etiological model for breast cancer is presented and it is indicated that the model accommodates most epidemiological aspects of breast cancer occurrence and natural history.

Trichopoulos D: Hypothesis: does breast cancer originate in utero?. Lancet. 1990, 335: 939-940. 10.1016/0140-6736(90)91000-Z.CrossRefPubMed

Trichopoulos D, Lipman R: Mammary gland mass and breast cancer risk. Epidemiology. 1992, 3: 523-526.CrossRefPubMed

Cole P, MacMahon B: Oestrogen fractions during early reproductive life in the aetiology of breast cancer. Lancet. 1969, 1: 604-606. 10.1016/S0140-6736(69)91537-2.CrossRefPubMed

Loeb LA: Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 1991, 51: 3075-3079.PubMed

Moolgavkar SH, Day NE, Stevens RG: Two-stage model for carcinogenesis: epidemiology of breast cancer in females. J Natl Cancer Inst. 1980, 65: 559-569.PubMed

DeWaard F, Trichopoulos D: A unifying concept of the aetiology of breast cancer. Int J Cancer. 1988, 41: 666-669.CrossRef

Ekbom A, Trichopoulos D, Adami H-O, Hsieh C-C, Lan S-J: Evidence of prenatal influences on breast cancer risk. Lancet. 1992, 340: 1015-1018. 10.1016/0140-6736(92)93019-J.CrossRefPubMed

Kaijser M, Granath F, Jacobsen G, Cnattingius S, Ekbom A: Maternal pregnancy estriol levels in relation to anamnestic and fetal anthropometric data. Epidemiology. 2000, 11: 315-319. 10.1097/00001648-200005000-00015.CrossRefPubMed

Innes KE, Byers TE: Preeclampsia and breast cancer risk. Epidemiology. 1999, 10: 722-732.CrossRefPubMed

10.

Potischman N, Troisi R: In-utero and early life exposures in relation to risk of breast cancer. Cancer Causes Control. 1999, 10: 561-573. 10.1023/A:1008955110868.CrossRefPubMed

11.

Vatten LJ, Maehle BO, Lund Nilsen TI, Tretli S, Hsieh C-C, Trichopoulos D, Stuver SO: Birth weight as a predictor of breast cancer: a case–control study in Norway. Br J Cancer. 2002, 86: 89-91. 10.1038/sj.bjc.6600011.CrossRefPubMedPubMedCentral

12.

Vatten LJ, Nilsen ST, Odegard RA, Romundstad PR, Austgulen R: Insulin-like growth factor I and leptin in umbilical cord plasma and infant birth size at term. Pediatrics. 2002, 109: 1131-1135.CrossRefPubMed

13.

Vatten LJ, Romundstad PR, Odegard RA, Nilsen ST, Trichopoulos D, Austgulen R: Alpha-foetoprotein in umbilical cord in relation to severe pre-eclampsia, birth weight and future breast cancer risk. Br J Cancer. 2002, 86: 728-731. 10.1038/sj.bjc.6600125.CrossRefPubMedPubMedCentral

14.

Schernhammer ES: In-utero exposures and breast cancer risk: joint effect of estrogens and insulin-like growth factor?. Cancer Causes Control. 2002, 13: 505-508. 10.1023/A:1016348425833.CrossRefPubMed

15.

Palmer JR, Hatch EE, Rosenberg CL, Hartge P, Kaufman RH, Titus-Ernstoff L, Noller KL, Herbst AL, Rao RS, Troisi R, Colton T, Hoover RN: Risk of breast cancer in women exposed to diethylstilbestrol in utero: preliminary results (United States). Cancer Causes Control. 2002, 13: 753-758. 10.1023/A:1020254711222.CrossRefPubMed

16.

Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, Hoover R, Haile R: Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst. 1995, 87: 1622-1629.CrossRefPubMed

17.

Boyd NF, Lockwood GA, Byng JW, Tritchler DL, Yaffe MJ: Mammographic densities and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 1998, 7: 1133-1144.PubMed

18.

Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE: Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res. 2000, 60: 3744-3748.PubMed

19.

Byrne C, Schairer C, Brinton LA, Wolfe J, Parekh N, Salane M, Carter C, Hoover R: Effects of mammographic density and benign breast disease on breast cancer risk (United States). Cancer Causes Control. 2001, 12: 103-110. 10.1023/A:1008935821885.CrossRefPubMed

20.

Berkel H, Birdsell DC, Jenkins H: Breast augmentation: a risk factor for breast cancer?. N Engl J Med. 1992, 326: 1649-1653.CrossRefPubMed

21.

Brinton LA, Lubin JH, Burich MC, Colton T, Brown SL, Hoover RN: Breast cancer following augmentation mammoplasty (United States). Cancer Causes Control. 2000, 11: 819-827. 10.1023/A:1008941110816.CrossRefPubMed

22.

Friis S, McLaughlin JK, Mellemkjaer L, Kjoller KH, Blot WJ, Boice JD, Fraumeni JF, Olsen JH: Breast implants and cancer risk in Denmark. Int J Cancer. 1997, 71: 956-958. 10.1002/(SICI)1097-0215(19970611)71:6<956::AID-IJC8>3.0.CO;2-X.CrossRefPubMed

23.

Adami H-O, Signorello LB, Trichopoulos D: Towards an understanding of breast cancer etiology. Semin Cancer Biol. 1998, 8: 255-262. 10.1006/scbi.1998.0077.CrossRefPubMed

24.

Brown MH, Weinberg M, Chong N, Levine R, Holowaty E: A cohort study of breast cancer risk in breast reduction patients. Plast Reconstr Surg. 1999, 103: 1674-1681. 10.1097/00006534-199905060-00015.CrossRefPubMed

25.

Boice JD, Persson I, Brinton LA, Hober M, McLaughlin JK, Blot WJ, Fraumeni JF, Nyren O: Breast cancer following breast reduction surgery in Sweden. Plast Reconstr Surg. 2000, 106: 755-762. 10.1097/00006534-200009040-00001.CrossRefPubMed

26.

Brinton LA, Persson I, Boice JD, McLaughlin JK, Fraumeni JF: Breast cancer risk in relation to amount of tissue removed during breast reduction operations in Sweden. Cancer. 2001, 91: 478-483. 10.1002/1097-0142(20010201)91:3<478::AID-CNCR1025>3.0.CO;2-5.CrossRefPubMed

27.

Swanson CA, Coates RJ, Schoenberg JB, Malone KE, Gammon MD, Stanford JL, Shorr IJ, Potischman NA, Brinton LA: Body size and breast cancer risk among women under age 45 years. Am J Epidemiol. 1996, 143: 698-706.CrossRefPubMed

28.

Egan KM, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Baron JA, Willett WC, Stampfer MJ, Trichopoulos D: The relation of breast size to breast cancer risk in postmenopausal women (United States). Cancer Causes Control. 1999, 10: 115-118. 10.1023/A:1008801131831.CrossRefPubMed

29.

Russo J, Romero AI, Russo IH: Architectural pattern of the normal and cancerous breast under the influence of parity. Cancer Epidemiol Biomark Prev. 1994, 3: 219-224.

30.

Sivaraman L, Medina D: Hormone-induced protection against breast cancer. J Mammary Gland Biol Neoplasia. 2002, 7: 77-92. 10.1023/A:1015774524076.CrossRefPubMed

31.

Lawson JS, Field AS, Champion S, Tran D, Ishikura H, Trichopoulos D: Low estrogen receptor a expression in normal breast tissue underlies low breast cancer incidence in Japan. Lancet. 1999, 354: 1787-1788. 10.1016/S0140-6736(99)04936-3.CrossRefPubMed

32.

Schrag D, Kuntz KM, Garber JE, Weeks JC: Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA. 2000, 283: 617-624. 10.1001/jama.283.5.617.CrossRefPubMed

Titel: Intrauterine environment, mammary gland mass and breast cancer risk
verfasst von: Dimitrios Trichopoulos
Publikationsdatum: 01.02.2002
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe 1/2002
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr555

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Intrauterine environment, mammary gland mass and breast cancer risk

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2002

Lack of evidence for an association of Epstein–Barr virus infection with breast carcinoma

The role of the ubiquitination-proteasome pathway in breast cancer: Ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer

Complex roles for telomeres and telomerase in breast carcinogenesis

Expression of glucocorticoid and progesterone nuclear receptor genes in archival breast cancer tissue

The role of the ubiquitination-proteasome pathway in breast cancer: Use of mouse models for analyzing ubiquitination processes

Centrosome cycle studies reveal promising candidates for anti-cancer drug design

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie